| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 8-K: Other Events |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Worldwide revenue of $389.9 million in the third quarter of 2026 |
| 22 Oct 2026 |
8-K: Other Events
As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings... |
| 14 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
A special meeting of stockholders (the “special meeting”) of Lantheus Holdings, Inc. (“Lantheus”) was held on October 14, 2026. A total of 57,184,503 shares of Lantheus common stock, out of a total of 65,299,875 shares of Lantheus common... |
| 02 Oct 2026 |
8-K: Other Events
As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings... |
| 21 Sep 2026 |
8-K: Other Events
As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Worldwide revenue of $388.2 million in the second quarter of 2026 |
| 04 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
Form of Certificate of Incorporation of the Surviving Corporation |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Strategic transaction would bring Curium’s theranostics portfolio and global manufacturing platform together with Lantheus’ complementary U.S. radiodiagnostics business |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026 |
| 01 May 2026 |
8-K: Material Modification to Rights of Security Holders; Departure/Election of Directors or Officers; Compensation +2 more
1. Purpose. The purpose of the Lantheus Holdings, Inc. Amended and Restated 2026 Equity Incentive Plan, originally adopted by the Board and approved by the stockholders of the Company on June 24, 2015 as the “Lantheus Holdings, Inc. 2015... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025 |
| 12 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 million |
| 11 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 million |
| 22 Jul 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
BEDFORD, Mass., July 22, 2025 – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. (“Life Molecular”), a ... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
BEDFORD, Mass., May 7, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliv... |
| 05 May 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Section 1.01. Annual Meetings. The annual meeting of the stockholders of Lantheus Holdings, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as properly may come before such meeting sh... |
| 01 Apr 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
BEDFORD, Mass., April 1, 2025 – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better pa... |
Loading...